Latest news for Buzzi (OTC:BZZUY) Stock

BUZZI UNICEM ADR

Buzzi SpA manufactures, distribute and sell cement, ready-mix concrete and aggregates. The company has geographical segments: Italy; Central Europe; Eastern Europe; and United States of America. It derives maximum revenue from United States of America.

Buzzi SpA

Buzzi

&nbsp;

<h2>Upgrades</h2>

<ul>
	<li>According to Benchmark, the prior rating for TopBuild Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>) was changed from Hold to Buy. In the second quarter, TopBuild showed an EPS of $2.76, compared to $1.68 from the year-ago quarter. At the moment, the stock has a 52-week-high of $235.50 and a 52-week-low of $144.58. TopBuild closed at $219.98 at the end of the last trading period.</li>
	<li>For Belden Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDC#NYSE">BDC</a>), Canaccord Genuity upgraded the previous rating of Hold to Buy. For the second quarter, Belden had an EPS of $1.21, compared to year-ago quarter EPS of $0.46. At the moment, the stock has a 52-week-high of $58.54 and a 52-week-low of $28.55. Belden closed at $56.96 at the end of the last trading period.</li>
	<li>For NeoPhotonics Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPTN#NYSE">NPTN</a>), Raymond James upgraded the previous rating of Underperform to Market Perform. For the second quarter, NeoPhotonics had an EPS of $0.22, compared to year-ago quarter EPS of $0.16. At the moment, the stock has a 52-week-high of $14.14 and a 52-week-low of $5.75. NeoPhotonics closed at $9.39 at the end of the last trading period.</li>
	<li>SVB Leerink upgraded the previous rating for HealthEquity Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) from Market Perform to Outperform. HealthEquity earned $0.40 in the second quarter, compared to $0.42 in the year-ago quarter. The stock has a 52-week-high of $93.32 and a 52-week-low of $45.82. At the end of the last trading period, HealthEquity closed at $63.18.</li>
	<li>For Biomarin Pharmaceutical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), Stifel upgraded the previous rating of Hold to Buy. In the second quarter, Biomarin Pharmaceutical showed an EPS of $0.07, compared to $0.16 from the year-ago quarter. At the moment, the stock has a 52-week-high of $92.56 and a 52-week-low of $71.35. Biomarin Pharmaceutical closed at $76.70 at the end of the last trading period.</li>
	<li>Stifel upgraded the previous rating for AppLovin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) from Hold to Buy. AppLovin earned $0.04 in the second quarter, compared to $0.10 in the year-ago quarter. At the moment, the stock has a 52-week-high of $90.03 and a 52-week-low of $49.41. AppLovin closed at $68.00 at the end of the last trading period.</li>
	<li>According to Jefferies, the prior rating for Banco Santander SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>) was changed from Underperform to Hold. Banco Santander earned $0.13 in the second quarter. At the moment, the stock has a 52-week-high of $4.38 and a 52-week-low of $1.78. Banco Santander closed at $3.61 at the end of the last trading period.</li>
</ul>

<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>

&nbsp;

<h2>Downgrades</h2>

<ul>
	<li>JP Morgan downgraded the previous rating for Humanigen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HGEN#NASDAQ">HGEN</a>) from Neutral to Underweight. In the second quarter, Humanigen showed an EPS of $1.20, compared to $0.79 from the year-ago quarter. At the moment, the stock has a 52-week-high of $29.20 and a 52-week-low of $7.50. Humanigen closed at $15.11 at the end of the last trading period.</li>
	<li>According to Macquarie, the prior rating for Score Media and Gaming Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCR#NASDAQ">SCR</a>) was changed from Outperform to Neutral. In the third quarter, Score Media and Gaming earned $0.63. The stock has a 52-week-high of $36.32 and a 52-week-low of $12.95. At the end of the last trading period, Score Media and Gaming closed at $35.46.</li>
	<li>According to Citigroup, the prior rating for Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) was changed from Buy to Neutral. Sherwin-Williams earned $2.65 in the second quarter, compared to $7.10 in the year-ago quarter. At the moment, the stock has a 52-week-high of $768.00 and a 52-week-low of $244.67. Sherwin-Williams closed at $296.69 at the end of the last trading period.</li>
	<li>According to Citigroup, the prior rating for Axalta Coating Systems Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) was changed from Buy to Neutral. Axalta Coating Sys earned $0.48 in the second quarter, compared to $0.15 in the year-ago quarter. At the moment, the stock has a 52-week-high of $34.20 and a 52-week-low of $21.43. Axalta Coating Sys closed at $29.07 at the end of the last trading period.</li>
	<li>According to Citigroup, the prior rating for PPG Industries Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) was changed from Buy to Neutral. In the second quarter, PPG Industries showed an EPS of $1.94, compared to $0.99 from the year-ago quarter. The current stock performance of PPG Industries shows a 52-week-high of $182.97 and a 52-week-low of $116.95. Moreover, at the end of the last trading period, the closing price was at $151.02.</li>
	<li>Mizuho downgraded the previous rating for Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>) from Neutral to Underperform. In the second quarter, Eversource Energy showed an EPS of $0.79, compared to $0.76 from the year-ago quarter. The stock has a 52-week-high of $96.66 and a 52-week-low of $76.64. At the end of the last trading period, Eversource Energy closed at $91.89.</li>
	<li>For Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), Stifel downgraded the previous rating of Buy to Hold. Vertex Pharmaceuticals earned $3.11 in the second quarter, compared to $2.61 in the year-ago quarter. The current stock performance of Vertex Pharmaceuticals shows a 52-week-high of $280.99 and a 52-week-low of $185.32. Moreover, at the end of the last trading period, the closing price was at $191.37.</li>
	<li>Morgan Stanley downgraded the previous rating for Cisco Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) from Overweight to Equal-Weight. For the fourth quarter, Cisco Systems had an EPS of $0.84, compared to year-ago quarter EPS of $0.80. The current stock performance of Cisco Systems shows a 52-week-high of $60.27 and a 52-week-low of $35.28. Moreover, at the end of the last trading period, the closing price was at $58.68.</li>
	<li>For Kadmon Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDMN#NASDAQ">KDMN</a>), Jefferies downgraded the previous rating of Buy to Hold. Kadmon Holdings earned $0.18 in the second quarter, compared to $0.17 in the year-ago quarter. At the moment, the stock has a 52-week-high of $9.20 and a 52-week-low of $3.15. Kadmon Holdings closed at $9.07 at the end of the last trading period.</li>
</ul>

<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>

&nbsp;

<h2>Initiations</h2>

<ul>
	<li>JP Morgan initiated coverage on Westport Fuel Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WPRT#NASDAQ">WPRT</a>) with a Neutral rating. The price target for Westport Fuel Systems is set to $5.00. For the second quarter, Westport Fuel Systems had an EPS of $0.11, compared to year-ago quarter EPS of $0.02. The stock has a 52-week-high of $12.95 and a 52-week-low of $1.55. At the end of the last trading period, Westport Fuel Systems closed at $3.67.</li>
	<li>Citigroup initiated coverage on Lucid Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) with a Buy rating. The price target for Lucid Gr is set to $28.00. &nbsp;Moreover, at the end of the last trading period, the closing price was at $18.93.</li>
	<li>UBS initiated coverage on Zogenix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZGNX#NASDAQ">ZGNX</a>) with a Buy rating. The price target for Zogenix is set to $23.00. In the second quarter, Zogenix showed an EPS of $1.05, compared to $0.96 from the year-ago quarter. At the moment, the stock has a 52-week-high of $25.31 and a 52-week-low of $13.01. Zogenix closed at $14.60 at the end of the last trading period.</li>
	<li>Stephens &amp; Co. initiated coverage on Apollo Endosurgery Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEN#NASDAQ">APEN</a>) with an Overweight rating. The price target for Apollo Endosurgery is set to $15.00. In the second quarter, Apollo Endosurgery showed an EPS of $0.22, compared to $0.30 from the year-ago quarter. The stock has a 52-week-high of $10.00 and a 52-week-low of $1.25. At the end of the last trading period, Apollo Endosurgery closed at $9.64.</li>
	<li>With a Neutral rating, Arete Research initiated coverage on Discovery Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DISCA#NASDAQ">DISCA</a>). The price target seems to have been set at $30.00 for Discovery. Discovery earned $0.92 in the second quarter, compared to $0.77 in the year-ago quarter. At the moment, the stock has a 52-week-high of $78.14 and a 52-week-low of $19.07. Discovery closed at $26.98 at the end of the last trading period.</li>
	<li>With a Buy rating, Arete Research initiated coverage on The Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>). The price target seems to have been set at $263.00 for Walt Disney. Walt Disney earned $0.80 in the third quarter, compared to $0.08 in the year-ago quarter. The stock has a 52-week-high of $203.02 and a 52-week-low of $117.23. At the end of the last trading period, Walt Disney closed at $185.15.</li>
	<li>With a Buy rating, Arete Research initiated coverage on Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>). The price target seems to have been set at $735.00 for Netflix. For the second quarter, Netflix had an EPS of $2.97, compared to year-ago quarter EPS of $1.59. The current stock performance of Netflix shows a 52-week-high of $615.60 and a 52-week-low of $458.60. Moreover, at the end of the last trading period, the closing price was at $606.05.</li>
	<li>HSBC initiated coverage on Kimberly-Clark Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) with a Hold rating. The price target for Kimberly-Clark is set to $131.00. For the second quarter, Kimberly-Clark had an EPS of $1.47, compared to year-ago quarter EPS of $2.20. The stock has a 52-week-high of $155.45 and a 52-week-low of $128.02. At the end of the last trading period, Kimberly-Clark closed at $141.49.</li>
	<li>Needham initiated coverage on Upwork Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) with a Buy rating. The price target for Upwork is set to $57.00. Upwork earned $0.03 in the second quarter, compared to $0.09 in the year-ago quarter. The stock has a 52-week-high of $64.49 and a 52-week-low of $13.46. At the end of the last trading period, Upwork closed at $43.98.</li>
	<li>With a Buy rating, B of A Securities initiated coverage on Arvinas Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>). The price target seems to have been set at $110.00 for Arvinas. In the second quarter, Arvinas showed an EPS of $1.03, compared to $0.65 from the year-ago quarter. At the moment, the stock has a 52-week-high of $108.47 and a 52-week-low of $19.68. Arvinas closed at $91.88 at the end of the last trading period.</li>
	<li>SVB Leerink initiated coverage on Myovant Sciences Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYOV#NYSE">MYOV</a>) with a Market Perform rating. The price target for Myovant Sciences is set to $24.00. Myovant Sciences earned $0.67 in the first quarter, compared to $0.37 in the year-ago quarter. The current stock performance of Myovant Sciences shows a 52-week-high of $30.90 and a 52-week-low of $13.42. Moreover, at the end of the last trading period, the closing price was at $25.81.</li>
	<li>With a Market Perform rating, SVB Leerink initiated coverage on scPharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPH#NASDAQ">SCPH</a>). The price target seems to have been set at $6.00 for scPharmaceuticals. In the second quarter, scPharmaceuticals showed an EPS of $0.26, compared to $0.36 from the year-ago quarter. At the moment, the stock has a 52-week-high of $9.64 and a 52-week-low of $4.75. scPharmaceuticals closed at $5.95 at the end of the last trading period.</li>
	<li>Credit Suisse initiated coverage on SoFi Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) with a Neutral rating. The price target for SoFi Technologies is set to $16.50. SoFi Technologies earned $0.48 in the second quarter, compared to $0.03 in the year-ago quarter. The current stock performance of SoFi Technologies shows a 52-week-high of $24.95 and a 52-week-low of $13.56. Moreover, at the end of the last trading period, the closing price was at $15.47.</li>
	<li>MKM Partners initiated coverage on Denbury Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEN#NYSE">DEN</a>) with a Buy rating. The price target for Denbury is set to $96.00. Denbury earned $0.61 in the second quarter, compared to $0.07 in the year-ago quarter. At the moment, the stock has a 52-week-high of $81.37 and a 52-week-low of $15.43. Denbury closed at $70.06 at the end of the last trading period.</li>
	<li>With an Overweight rating, JP Morgan initiated coverage on Blade Air Mobility Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>). The price target seems to have been set at $16.00 for Blade Air Mobility. Blade Air Mobility earned $0.15 in the third quarter. At the moment, the stock has a 52-week-high of $11.87 and a 52-week-low of $6.41. Blade Air Mobility closed at $8.79 at the end of the last trading period.</li>
</ul>

<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Upgrades

Downgrades

Initiation

Intraday Update

Analyst Ratings

ALGS

AMRN

APEN

ARVN

AVIR

AXTA

BDRFY

BLDE

BMRN

BYSI

BZZUY

CFRX

CSCO

DISCA

ENTA

GSHD

HENKY

HGEN

HLLY

HYZN

IFSUF

KDMN

LBRT

LCID

LESL

MYOV

NFLX

NPTN

ONXXF

ORGN

PDRDY

RKLB

RKLY

SCPH

SOFI

UPWK

VOSSY

VRTX

WPRT

ZGNX

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021

Exane BNP Paribas downgrades Buzzi Unicem (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BZZUY#OTC">BZZUY</a>) from Outperform to Neutral.

News

Exane BNP Paribas Downgrades Buzzi Unicem to Neutral

Comments

Buzzi

News

Latest news for Buzzi (OTC:BZZUY) Stock

Thursday, September 09, 2021

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga